guest ::
| Home > Publications database > Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors. > print |
| Home > Publications database > Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors. > print |
| 001 | 294035 | ||
| 005 | 20241017182108.0 | ||
| 024 | 7 | _ | |a 10.1158/1078-0432.CCR-23-3489 |2 doi |
| 024 | 7 | _ | |a pmid:39120581 |2 pmid |
| 024 | 7 | _ | |a 1078-0432 |2 ISSN |
| 024 | 7 | _ | |a 1557-3265 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-02063 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Fincke, Victoria E |0 0000-0001-7488-6885 |b 0 |
| 245 | _ | _ | |a Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors. |
| 260 | _ | _ | |a Philadelphia, Pa. [u.a.] |c 2024 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1729158493_4973 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:B062# |
| 520 | _ | _ | |a Extracranial malignant rhabdoid tumors (eMRT) are a challenging entity. Despite the use of multimodal treatment approaches, therapy failure occurs in 55% to 67% of these. Molecular markers for identification of patients at increased risk for relapse or refractory (R/R) disease are not available. Clinical characteristics may only insufficiently predict the individual course of disease.Using the EU-RHAB database, we analyzed a cohort of 121 patients with eMRT clinically. For 81 patients, molecular and clinical data were available, which were further complemented with publicly available DNA molecular data from 92 eMRTs. We aimed to delineate molecular risk factors by dissecting the DNA methylome of these tumors. Moreover, we establish clinical characteristics and treatment details of R/R disease in a subcohort of 80 patients.Using consensus hierarchical clustering, we identified three distinct subgroups, one of which (eMRT standard risk) was associated with significantly improved survival, irrespective of germline status and/or localization. At the transcriptome level, this subgroup was characterized by an overexpression of genes involved in muscle development. A relevant proportion of patients developed distant relapses or progressions; the median time to the event was 4 months, underlining the need for early identification and risk stratification of R/R disease. The overall survival was significantly decreased in patients with progressive disease when compared with relapse cases, and reaching complete remission during salvage therapy provided a survival benefit.Our analysis of eMRT in this comprehensive cohort provides novel insights into the patterns of relapse and integrates molecular and clinical risk factors to guide clinical decision-making. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Biomarkers, Tumor |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Rhabdoid Tumor: genetics |2 MeSH |
| 650 | _ | 2 | |a Rhabdoid Tumor: pathology |2 MeSH |
| 650 | _ | 2 | |a Rhabdoid Tumor: therapy |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Risk Factors |2 MeSH |
| 650 | _ | 2 | |a Child, Preschool |2 MeSH |
| 650 | _ | 2 | |a Biomarkers, Tumor: genetics |2 MeSH |
| 650 | _ | 2 | |a Infant |2 MeSH |
| 650 | _ | 2 | |a Child |2 MeSH |
| 650 | _ | 2 | |a Prognosis |2 MeSH |
| 650 | _ | 2 | |a DNA Methylation |2 MeSH |
| 650 | _ | 2 | |a Neoplasm Recurrence, Local: genetics |2 MeSH |
| 650 | _ | 2 | |a Neoplasm Recurrence, Local: pathology |2 MeSH |
| 650 | _ | 2 | |a Adolescent |2 MeSH |
| 650 | _ | 2 | |a Transcriptome |2 MeSH |
| 650 | _ | 2 | |a Gene Expression Profiling |2 MeSH |
| 700 | 1 | _ | |a Steinbügl, Mona |0 0009-0000-1501-3064 |b 1 |
| 700 | 1 | _ | |a Chun, Hye-Jung E |0 0009-0005-1911-9487 |b 2 |
| 700 | 1 | _ | |a Nemes, Karolina |0 0000-0003-0270-5875 |b 3 |
| 700 | 1 | _ | |a Mucha, Marlena |0 0000-0001-9009-3383 |b 4 |
| 700 | 1 | _ | |a Loßner, Maurice |0 0009-0009-6414-8550 |b 5 |
| 700 | 1 | _ | |a Dorn, Felix |0 0009-0000-0223-9654 |b 6 |
| 700 | 1 | _ | |a Gastberger, Katharina |0 0000-0002-2211-6720 |b 7 |
| 700 | 1 | _ | |a Bühner, Sebastian |0 0009-0003-2308-477X |b 8 |
| 700 | 1 | _ | |a Sill, Martin |0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b |b 9 |
| 700 | 1 | _ | |a Kröncke, Thomas |0 0000-0003-4889-1036 |b 10 |
| 700 | 1 | _ | |a Siebert, Reiner |0 0000-0001-7433-3703 |b 11 |
| 700 | 1 | _ | |a Melchior, Patrick |0 0000-0003-2305-8857 |b 12 |
| 700 | 1 | _ | |a Furtwängler, Rhoikos |0 0000-0002-1967-8343 |b 13 |
| 700 | 1 | _ | |a Schlesner, Matthias |b 14 |
| 700 | 1 | _ | |a Vokuhl, Christian |0 0009-0003-6596-1419 |b 15 |
| 700 | 1 | _ | |a Röcken, Christoph |0 0000-0002-6989-8002 |b 16 |
| 700 | 1 | _ | |a Johann, Pascal |0 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8 |b 17 |e Last author |
| 700 | 1 | _ | |a Frühwald, Michael C |0 0000-0002-8237-1854 |b 18 |
| 773 | _ | _ | |a 10.1158/1078-0432.CCR-23-3489 |g Vol. 30, no. 20, p. 4667 - 4680 |0 PERI:(DE-600)2036787-9 |n 20 |p 4667 - 4680 |t Clinical cancer research |v 30 |y 2024 |x 1078-0432 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:294035 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 0000-0003-4889-1036 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-25 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN CANCER RES : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b CLIN CANCER RES : 2022 |d 2023-08-25 |
| 920 | 2 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|